Chronic, heavy alcohol consumption may affect the concentration of neurometabolites assessed with proton magnetic resonance spectroscopy ( 1 H-MRS). We investigated the largest sample reported to date (N ¼ 213) with the primary goal of determining how specific clinical features impact neurometabolite concentrations in an anterior cingulate gray matter voxel. This community-dwelling sample included both treatment-seeking and non-treatment-seeking individuals. A healthy control group (N ¼ 66) was matched for age and education. In multivariate analyses predicting neurometabolite concentrations, the heavy drinking group had greater concentrations overall. An age by group interaction was noted, as group difference across neurometabolites increased with age. More years drinking, but not more drinks per drinking day (DPDD), predicted greater concentrations of cholinecontaining compounds (Cho), creatine-phosphocreatine (Cre), glutamate-glutamine (Glx), and N-acetyl-aspartate (NAA). The effects of other clinical variables (depression, cigarette smoking, marijuana use) were negligible. After controlling for DPDD and years drinking, treatment-seeking status had no impact on neurometabolites. In the very oldest portion of the sample (mean age ¼ 50), however, a negative relationship was seen between NAA and years drinking. These results suggest that the nature of neurometabolite abnormalities in chronic heavy drinkers may vary as a function of duration of abuse.
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Introduction
Proton magnetic resonance spectroscopy ( 1 H-MRS) is a useful tool for identifying abnormality of brain metabolites in individuals with alcohol use disorders (AUD) and histories of heavy drinking. In contrast to other common neuroimaging modalities, 1 H-MRS investigates the metabolic milieu of working neurons, providing insights on neural integrity, energy metabolism, and membrane turnover. A rich 1 H-MRS literature has emerged characterizing both psychiatric disorders (Maddock and Buonocore, 2012) and brain injury (Yeo et al., 2011) , providing an informative context in which to interpret results from studies of chronic, heavy alcohol consumption.
A recent review of MRS studies of alcohol abuse (Meyerhoff et al., 2011) notes the need to elucidate the impact of comorbid conditions such as smoking or depression on neurometabolite concentrations. Variation in the severity and duration of alcohol abuse also likely contributes to the observed clinical heterogeneity in MRS findings. Moreover, individuals who are actively seeking treatment may differ from those who are not on a number of potentially salient dimensions (Smith and Fein, 2010) . Treatment-seeking status overlaps with severity and chronicity of alcohol consumption, as well as with comorbid substance use disorders and general psychopathology (Cohen et al., 2007; Fein and Landman, 2005) . To date, one study directly compared brain metabolite levels in treatment-seeking and non-treatment-seeking individuals with AUD, reporting lower N-acetyl aspartate (NAA), choline-containing compounds (Cho), and myoinositol (mI) in the treatment-seeking group (Gazdzinski et al., 2008) . For the most part, these differences were not accounted for by demographic factors, drinking severity, comorbid psychopathology, or other clinical variables.
Two major methodological issues have limited ability to delineate these and other sources of within-group variability. 
